Dr. Oz: Silver Bullet Weight Loss Pill | Qnexa

Qnexa: The New Diet Pill

Qnexa: Dr. Oz explores weight-loss drug Qnexa: Is it safe? What are the risks? “THE NEW SILVER BULLET FOR WEIGHT LOSS!”: Today Qnexa is the topic of discussion on Dr. Oz. Qnexa is poised to become the first FDA-approved weight-loss pill in 13 years

“Qnexa” is designed for people who are obese, which is roughly 30 or more pounds over a healthy weight, or those who are overweight and have other weight-related health issues such as high blood pressure, type 2 diabetes or high cholesterol.

The company’s research on Qnexa shows that people lose 10% to 11% of their starting weight in a year.

Remember fen-phen? The fenfluramine-phentermine “fen-phen” combo weight-loss drug was pulled from shelves in the late 1990s because of the risk of a rare and often fatal lung disease, pulmonary hypertension, as well as heart damage.

Dr. Oz: Silver Bullet Weight Loss Pill

Dr Oz explores the potential of this super weight-loss pill Qnexa and what it means in the fight against obesity. Researchers claim it curbs your appetite, reduces food cravings, and even changes the way your food tastes. Could this pill be right for you? Today's Guests Dr. Craig Primack, Chris Powell both give their view points on Qnexa weight loss pills.

Craig Primack MD, FAAP, Obesity Medicine Specialist, Co-director, Scottsdale Weight Loss Center told Dr. Oz that he has been prescribing these two drugs for weight loss, phentermine and topamax individually of course, along with many other doctors. These two drugs are powerful and work for weight loss and as you increase the doses there are more potential side effects. In the new combined drug diet pill they are actually able to decrease the dose of both the drugs phentermine and topiramate, causing less side effects and maybe even the drugs themselves are cancelling out the side effects of the other one says Dr. Primack.

Qnexa is a combination pill of two medicines already on the market: phentermine and extended-release topiramate. Both drugs have been shown to help weight loss when used as part of a comprehensive weight-loss program

What is Qnexa

Qnexa (phentermine and topiramate) Extended-release Capsules is an investigational, once-per-day, weight-loss therapy that combines low doses of two agents approved by the Food and Drug Administration (FDA), phentermine and topiramate, in a controlled-release formulation.


Phentermine was initially approved as a weight-loss drug in 1959. Phentermine is considered a stimulant-type appetite suppressant. Its major site of action is centrally in the brain. It effectively decreases hunger and gently increases metabolism. Phentermine has been studied numerous times for weight loss (in combination with diet and behavioral modification), as well as in the maintenance of weight loss.


Topiramate (Topamax®, Janssen Pharmaceuticals, Inc., Titusville, New Jersey) was originally approved in 1996 as a migraine-preventative treatment and seizure medication. Weight loss was initially seen as a side effect and it has now been studied directly for use in weight loss and in binge-eating disorder. The mechanism of action of topiramate is not entirely known. One mechanism that may contribute to its weight loss effects is its effect on taste. Many patients taking this drug report certain foods taste different, especially diet colas. With altered taste sensations, some of the reward from eating certain foods may be altered.

On February 22, 2012, a subcommittee of the FDA voted 22 to 2 to approve the drug. On July 17, 2012, the full FDA is expected to follow the sub-committee recommendation and approve Qnexa. It will likely be 3 to 6 months after approval before Qnexa is available for use.